Identification of a Subset of Stage I Colorectal Cancer Patients With High Recurrence Risk

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Identifying predictive biomarkers for early-stage colorectal cancer (CRC) recurrence is crucial.
• Focal adhesion kinase (FAK), a tyrosine kinase, is implicated in cancer invasion and metastasis.
• FAK presents a potential clinically adaptable biomarker for CRC risk stratification.

Purpose of the Study:

• To investigate the prognostic value of focal adhesion kinase (FAK) expression in predicting recurrence in early-stage colorectal cancer (CRC).
• To determine if FAK expression levels correlate with survival outcomes in CRC patients.

Main Methods:

• Assessed FAK expression using immunohistochemistry on tissue microarrays from an initial cohort of 298 CRC patients and a validation cohort of 517 early-stage CRC patients.
• Dichotomized FAK expression into high and low levels for correlation with clinicopathological features and survival.
• Performed multivariable survival analysis to identify independent predictors of recurrence-free survival (RFS).

Main Results:

• FAK overexpression was an early event in CRC progression, increasing from normal colon to stage I and II, but not higher stages.
• High FAK expression was significantly associated with decreased 10-year recurrence-free survival (RFS) in stage I CRC patients in both initial (P=.02) and validation (P=.004) cohorts.
• Multivariable analysis identified FAK (HR=5.27) and perineural invasion (HR=7.38) as significant predictors of RFS in stage I CRC; FAK was the sole significant factor across RFS, overall, and disease-specific survivals.

Conclusions:

• High FAK expression identifies a subset of stage I CRC patients at high risk for recurrence and reduced survival, indicating significant prognostic value.
• These findings suggest that FAK can serve as a prognostic biomarker for early-stage CRC.
• Patients identified with high FAK expression may benefit from intensified surveillance protocols for recurrent disease.